Enhancing Cancer Immunotherapy with Artificial Intelligence
Physicians may soon use artificial intelligence (AI) and medical images to study tumors without a biopsy. The techniques developed to study tumors in this new way are described in the September 1 issue of The Lancet Oncology. Along with helping physicians learn more about tumors without surgery, the new approach should help identify which cancer patients will respond best to cutting-edge immunotherapy treatments. The AI techniques could be useful for “predicting clinical outcomes of patients treated with immunotherapy when validated by further prospective randomized trials,” the authors wrote. Immunotherapy tre...
Source: Asbestos and Mesothelioma News - September 19, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel Mesothelioma Treatment Closer to FDA Approval
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth. In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option. “At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company...
Source: Asbestos and Mesothelioma News - September 17, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Ripley Named New Director of Mesothelioma Center at Baylor
Thoracic surgeon Dr. R. Taylor Ripley comes to the Mesothelioma Treatment Center at Baylor College of Medicine with the highest possible endorsement. Dr. David Sugarbaker, the world’s most prominent mesothelioma specialist and former director of the prestigious Baylor Lung Institute, recruited Ripley. It was like being anointed by the king. Ripley spent the previous four years at the National Cancer Institute (NCI) in Bethesda, Maryland, where he built a sterling reputation for surgical, clinical and investigational research excellence. “Dr. Sugarbaker wanted someone to help grow his program. He recruited me to...
Source: Asbestos and Mesothelioma News - September 12, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Dr. R. Taylor Ripley Leads Mesothelioma Center at Baylor
Thoracic surgeon Dr. R. Taylor Ripley comes to the Mesothelioma Treatment Center at Baylor College of Medicine with the highest possible endorsement. Dr. David Sugarbaker, the world’s most prominent mesothelioma specialist and director of the prestigious Baylor Lung Institute, recruited Ripley. It was like being anointed by the king. Ripley spent the previous four years at the National Cancer Institute (NCI) in Bethesda, Maryland, where he built a sterling reputation for surgical, clinical and investigational research excellence. “Dr. Sugarbaker wanted someone to help grow his program. He recruited me to do tha...
Source: Asbestos and Mesothelioma News - September 12, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Surgery for Mesothelioma No Longer Recommended in UK
Aggressive surgery for the treatment of malignant pleural mesothelioma (MPM) — unless part of a clinical trial — is no longer being recommended in the United Kingdom. The British Thoracic Society recently published its Mesothelioma Management Guidelines for 2018 and removed surgery from its recommendations. The belief was that potential harm was not worth the risk. The backtrack on surgery included the extrapleural pneumonectomy (EPP), the extended pleurectomy and decortication (P/D) and the partial pleurectomy (PP) — all of which are being done at cancer centers in the United States. “Surgery is a ...
Source: Asbestos and Mesothelioma News - September 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

9/11 Cancer Deaths Continue to Rise
John Feal believes more people will die from illnesses related to 9/11 than from the terrorist attack at the World Trade Center. He should know. He’s a first responder who witnesses it every day. And he is not alone in his belief. Feal, a longtime advocate for Sept. 11 survivors and those dying from diseases related to the terrorist attacks, will again host the annual naming ceremony at the 9/11 Responders Remembered Park in Smithtown, Long Island. Each year he reads the names of those who have died within the past year. And each year, the list is longer than the last. On the 17th anniversary of the terrorist attack...
Source: Asbestos and Mesothelioma News - September 10, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Alternative Cancer Treatment Clinic Reopening in Bahamas
Jerry Lampe and Ruth Phillips — two of America’s longest-living mesothelioma survivors — won’t feel so helpless now when a newly diagnosed patient asks for their secret to success. The controversial Immune Augmentation Therapy (IAT) Clinic in Freeport, Bahamas, is set to reopen in October, giving mesothelioma patients a proven, alternative therapy option once again. IAT operated outside of U.S. regulation from 1977 to 2016. The name has been changed to Quantum Immunologics, but the philosophy surrounding cancer treatment is exactly the same, a throwback to when Lampe and Phillips were treated origi...
Source: Asbestos and Mesothelioma News - September 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Florida Developer Sentenced on Negligent Asbestos Removal
A Florida real estate developer has been sentenced on a single misdemeanor count of negligent removal of asbestos and putting workers in imminent danger from the cancer-causing mineral. In addition to 48 months of probation, Philip J. Farley III was ordered to pay $250,000 to fund a treatment and medical monitoring program for 90 workers who may have been exposed to asbestos during a renovation project in downtown St. Petersburg, Florida, in 2010. The sentencing comes three years after Farley was indicted on several federal charges. Farley reportedly hired cheap labor to start a massive renovation of a 480-unit complex now...
Source: Asbestos and Mesothelioma News - August 31, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Dr. David Sugarbaker, Mesothelioma Treatment Pioneer, Dies at 65
Thoracic surgeon Dr. David Sugarbaker, a world leader in advancing the treatment of pleural mesothelioma for nearly 30 years, has died. He was 65. Sugarbaker was director of the Lung Institute at the Baylor College of Medicine in Houston. Dr. Raja Flores, thoracic surgeon and mesothelioma specialist at Mount Sinai Cancer Center, expressed his respect for the famed surgeon. “He was a giant in the field. He not only took care of the mesothelioma patients, he trained a whole generation of doctors who will continue taking care of those patients,” said Flores, who trained under Sugarbaker. “It’s a sad...
Source: Asbestos and Mesothelioma News - August 29, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

What ’s Included in the EPA’s New Asbestos Use Rule?
The United States Environmental Protection Agency (EPA) is moving forward with a proposed rule critics fear will expand the commercial use of asbestos — a toxic mineral known to cause mesothelioma and other diseases. The EPA received nearly 6,000 comments about its significant new use rule (SNUR) as of Aug. 10, the last day for public commenting. In June, the agency proposed SNUR under the reformed Toxic Substances Control Act (TSCA). It would allow companies to manufacture, import and process more than a dozen asbestos-containing products no longer in use as long as the EPA approves them first. The EPA’s summa...
Source: Asbestos and Mesothelioma News - August 24, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Mesothelioma Specialty Centers Rank on Best Hospitals List
The MD Anderson Cancer Center in Houston was named the No. 1 cancer care hospital in America by U.S. News & World Report for the fourth consecutive year. MD Anderson has been a leading specialty center for pleural mesothelioma treatment, which contributed to its top billing in the 2018-19 rankings. The center is in the recruiting or active-and-not recruiting stage for 15 different clinical trials involving mesothelioma. Memorial-Sloan Kettering Cancer Center in New York, the Mayo Clinic in Rochester, Minnesota, Dana-Farber and Brigham and Women’s Hospital in Boston, and the Cleveland Clinic, respectively, round ...
Source: Asbestos and Mesothelioma News - August 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Radiofrequency Ablation Fixes Mesothelioma Recurrence in Case Study
Radiofrequency ablation (RFA) has been used successfully in Japan to treat post-surgery recurrence of malignant pleural mesothelioma, according to a case study published recently by the Society of Thoracic Surgeons. Although RFA has been utilized for several years to treat various thoracic lesions, the study authors believe this is the first time it worked effectively with mesothelioma cancer cells. “It shows promising efficacy,” the authors wrote. “Radiofrequency should be considered an option for treating recurrence of MPM [malignant pleural mesothelioma].” RFA is a minimally invasive medical proc...
Source: Asbestos and Mesothelioma News - August 15, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Moving Toward an Earlier Diagnosis of Mesothelioma
This study provided proof of concept for the presence of ctDNA in blood of treatment-naive MPM [malignant pleural mesothelioma] patients by the detection of somatic variants that were identified by analysis of a tumor sample,” the authors wrote. “This opens perspective towards its use in MPM.” The post Moving Toward an Earlier Diagnosis of Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - August 13, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Improving Surgery for Mesothelioma with Glowing Tumor Technology
Thoracic surgeon Dr. Sunil Singhal at the Abramson Cancer Center has developed glowing tumor technology that should increase the effectiveness of aggressive surgery for malignant pleural mesothelioma. Singhal has shown recently that by adding a contrast agent that makes tumor cells glow, a more complete surgery can be done. This potentially avoids the now almost-inevitable cancer recurrence. “This is a big deal. We could potentially help a lot of patients with this,” Singhal told Asbestos.com. “It could change the entire field [of surgery for mesothelioma].” Singhal and his colleagues from the Abram...
Source: Asbestos and Mesothelioma News - August 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Op-Ed: EPA Opens the Door to a Silent Killer — Asbestos
This article represents his opinions. The Environmental Protection Agency would like you to think it is taking an “unprecedented” stand against the hazards of asbestos, the mineral that kills nearly 40,000 Americans each year from mesothelioma, lung cancer and other asbestos-related diseases. It is not. In fact, on June 1, the EPA announced a significant new use rule (SNUR) that will allow companies to manufacture, import and process new asbestos-containing products after it evaluates their potential health dangers. The standards to evaluate those health risks, which are included in a nearly 1,500-page docume...
Source: Asbestos and Mesothelioma News - August 8, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Crayons Sold by Dollar Tree, Amazon Test Positive for Asbestos
A recent test from a consumer advocacy group found toxic levels of asbestos — a mineral that can lead to lung cancer and mesothelioma if inhaled or ingested — in a popular brand of crayons sold by Dollar Tree, Amazon.com and other retailers. The U.S. Public Interest Research Group (U.S. PIRG) Education Fund tested 36 packs of Playskool crayons purchased from a Dollar Tree store in Chicago. All contained dangerous amounts of tremolite asbestos fibers, according to Kara Cook-Schultz, toxics director for U.S. PIRG. The results were part of U.S. PIRG’s “Safer School Supplies: Shopping Guide,” rele...
Source: Asbestos and Mesothelioma News - August 7, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers Find New Mesothelioma Genes in Family Study
This study strengthens the suspicion that, next to germline BAP1 alterations, other genetic factors might predispose families to the development of MM,” the authors wrote. Mutations in only one gene called BAP1 have been shown to increase risk of mesothelioma. However, experts suspect other genes may play a role in the disease. This new study supports the idea that other genes can predispose a person — or even an entire family — to mesothelioma. Hints of Genetic Influence on Mesothelioma Risk Asbestos exposure is the No. 1 cause of mesothelioma. However, some families seem to have more cases of mesothe...
Source: Asbestos and Mesothelioma News - August 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Yale Study: Complementary Medicine Can Shorten Cancer Survival
Cancer patients — including those with mesothelioma — who receive complementary therapy are likely to die sooner than those who use only conventional treatment, according to researchers at Yale School of Medicine. Patients receiving complementary medicine also were more inclined to forego at least one component of their conventional treatment regimen. The study was done by a team from the Yale Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine. JAMA Oncology published the study July 19. “The study was about patients who were using unproven therapies for treatment...
Source: Asbestos and Mesothelioma News - August 1, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Radiation Therapy Can Increase Mesothelioma Survival Time
Too many patients with malignant pleural mesothelioma are going without adjuvant radiotherapy that could extend their lives significantly, according to Dr. Bin Teh at Houston Methodist Hospital in Texas. Teh is the senior author of a recent study — the largest of its kind — that examined the role and extent of radiation therapy in the overall treatment of mesothelioma. He and his colleagues found only 3.1 percent of patients diagnosed with pleural mesothelioma underwent radiotherapy treatment in combination with aggressive surgery. “Surgery plus radiation improves overall survival,” Teh, vice chair ...
Source: Asbestos and Mesothelioma News - July 30, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Fire Rips Through Forests Around Libby Asbestos Site
Specially trained firefighters, equipped with high-tech gear designed to prevent the inhalation of toxic asbestos fibers, continued battling forest fires into the weekend near Libby, Montana. The blaze remains at least a mile from the now-closed W.R. Grace vermiculite mine, but firefighters continued working with their full-faced respirators in the asbestos-laced forest. Libby is home to the longest-running, man-made environmental disaster in American history, stemming from more than 70 years (1919-1990) of mining vermiculite tainted by toxic asbestos. Hundreds of miners and nearby residents have died from asbestos-related...
Source: Asbestos and Mesothelioma News - July 27, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

PI3K Inhibitors and Keto Diet Better Than Drug Alone
Many mesothelioma experts believe the route to better disease management — and possibly a cure — lies with drugs that target genes and cell pathways that promote cancer growth. New research published July 4 in the journal Nature supports a novel approach for making PI3K inhibitors, medications that inhibit cancer growth, more effective. Trials on these drugs have been mixed, and now cancer experts may know why. PI3K inhibitors seem to work poorly in the presence of high glucose (sugar) and insulin levels. The new study in cells and mice shows reducing glucose and insulin with a ketogenic diet, popularly known ...
Source: Asbestos and Mesothelioma News - July 27, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Immunotherapy Clinical Trial Aims for Mesothelioma Cure
Medical oncologist Dr. Bernardo Goulart at the Seattle Cancer Care Alliance (SCCA) believes his latest clinical trial might be the most curative approach to treatment of pleural mesothelioma. He also believes it could work. Goulart is the principal investigator at SCCA, which has embraced a novel clinical trial that combines the immunotherapy drug Tecentriq (atezolizumab) with a multimodal regimen of chemotherapy, surgery and radiation. “The trial design is very intense, requiring multidisciplinary involvement,” Goulart told Asbestos.com. “I think it could provide insight into the next step of research th...
Source: Asbestos and Mesothelioma News - July 25, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving. Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer. A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce. “We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the Universit...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Asbestos Covers Parts of NYC After Steam Pipe Explosion
An underground steam pipe explosion and the resulting fountain of vapor filled with toxic asbestos fibers caused the evacuation of 28 buildings and the closing of several surrounding streets in New York City Thursday. Only five minor injuries were reported, but the force of the blast and the steady stream of smoke pouring from the resulting crater covered nearby buildings and sent commuters running for shelter. The fear of asbestos contamination dominated the early cleanup efforts. Inhaling or ingesting microscopic asbestos fibers can eventually lead to serious health problems, including asbestosis, lung cancer and mesothe...
Source: Asbestos and Mesothelioma News - July 19, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Trial Adds Gemcitabine to Pleural Mesothelioma HIOC Therapy
Results of a phase I clinical trial highlight how the addition of a drug to an existing treatment option appears safe and may improve outcomes in certain patients with malignant pleural mesothelioma (MPM). The primary goal of the trial was to determine the maximum tolerated dose of gemcitabine added to cisplatin when these drugs are delivered together as heated intraoperative chemotherapy (HIOC) during surgery. Researchers have studied cisplatin alone for HIOC. The addition of gemcitabine — a chemotherapy drug often used to treat pancreatic, ovarian and breast cancers — is new. The Journal of Thoracic Oncology...
Source: Asbestos and Mesothelioma News - July 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Researchers Find Link Between Vitamin D and Asbestosis
This study was not designed to explain whether supplementing with vitamin D will protect against asbestosis. This new research also does not examine if taking vitamin D will slow down the progression of existing ILD. Still, there are a lot of good reasons to pay attention to the sunshine vitamin. Regardless of whether a person has been exposed to asbestos, no one should ignore very low vitamin D levels. People already diagnosed with an asbestos-related cancer, may benefit from a quick check of vitamin D levels. According to the medical literature, up to 80 percent of people with cancer may be vitamin D deficient. People ca...
Source: Asbestos and Mesothelioma News - July 16, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

J & J Hit with $4.7B Verdict in Talc Asbestos Cancer Case
A Missouri jury Thursday ordered Johnson & Johnson to pay $4.69 billion to 22 women who claim asbestos in the company’s talc products caused them to develop ovarian cancer. It is the largest verdict to date the consumer goods giant has faced in an asbestos-talc case. The Circuit Court of the City of St. Louis handed down $550 million in compensatory damages and $4.14 billion in punitive damages in the verdict, averaging about $25 million apiece for the 22 plaintiffs. J&J currently faces roughly 9,000 cases that blame its talc products — including the company’s iconic Johnson’s Baby Powder &m...
Source: Asbestos and Mesothelioma News - July 13, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Russian Company Brands Asbestos with Trump ’ s Face
The world’s largest producer of chrysotile asbestos is now marketing its signature product with President Donald Trump’s image, according to a recent Facebook post from the Russian mining company Uralasbest. On June 25, the company, which operates a giant asbestos mine in the Ural Mountains in Western Russia, posted photos of its asbestos on palettes wrapped in plastic and stamped with a seal of Trump’s face in red ink. A message of support for Trump and former Environmental Protection Agency (EPA) administrator Scott Pruitt accompanied the photos. In an English translation provided by the Environmental...
Source: Asbestos and Mesothelioma News - July 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Surgery Plus HIPEC Only ‘ Potential for Cure ’ of Peritoneal Mesothelioma
This study contributes to a better understanding of how CRS and HIPEC work and who is likely to receive the best benefit from this combination treatment. For patients with the most aggressive peritoneal mesothelioma cancers, additional options — such as immunotherapy or ongoing, post-surgical delivery of chemotherapy into the peritoneal cavity — may be additional treatments to consider. The post Surgery Plus HIPEC Only ‘Potential for Cure’ of Peritoneal Mesothelioma appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 10, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study Details Significant Increase in Asbestos-Related Deaths
Deaths attributed to asbestos exposure — within the United States and worldwide — have been significantly underestimated, according to the latest study by the International Commission of Occupational Health (ICOH). Asbestos is killing more people than anyone thought. Based on the most extensive study to date, occupational asbestos-related diseases killed 39,275 people within the U.S. and 222,321 people throughout the world in 2016. Both figures were more than double the commonly used estimates that stem from various governmental and nongovernmental health agencies. “The asbestos burden is worse than peopl...
Source: Asbestos and Mesothelioma News - July 9, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Cancer Treatment Less Effective in Older Patients
As age increases, so does the risk for cancer. More than half of all cancer cases occur in people over 65. This is especially true for mesothelioma. The average age at diagnosis for pleural mesothelioma — the most common form of the disease — is 69. Despite cancer being more common among the elderly, many cancer treatments work best in younger patients. Researchers now have an idea of why certain cancer treatments don’t work as well in older patients. These important findings were published in June in the medical journal Cell Reports. “While it is clear that primary T cell responses decline in the ...
Source: Asbestos and Mesothelioma News - July 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Gene Mutations Dictate Treatment in NCI Clinical Trial
More than 40 patients with mesothelioma have been screened for NCI-MATCH, the novel clinical trial pairing tumor-related gene abnormalities with a drug targeting the corresponding mutation, regardless of cancer type. The multicenter program is the largest precision medicine clinical trial ever conducted, with more than 5,500 patients already participating nationwide. The National Cancer Institute (NCI) sponsors the phase II trial called Molecular Analysis for Therapy Choice (MATCH), which opened in 2015. The study was designed for patients with various solid tumors, myeloma and lymphoma that have progressed after standard-...
Source: Asbestos and Mesothelioma News - July 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Research Reveals Immunotherapy More Effective in Men
For mesothelioma patients, immunotherapy is mostly available through clinical trials at this time. Immunotherapy is a relatively new way to treat cancer, and doctors still are learning who will respond best to these novel therapies. Newly released medical research has found men seem to respond better to immunotherapy than women. But this doesn’t mean immunotherapy is off the table for women with mesothelioma. You should learn all you can about how immunotherapy works, why it may or may not be right for you and how you can best prepare yourself if you decide an immunotherapy clinical trial is right for you. Thorough ...
Source: Asbestos and Mesothelioma News - July 3, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Study: Intrapleural Air Flow Can Enhance Mesothelioma CT Scans
Researchers in Australia believe they have discovered a simple way to enhance the accuracy of CT scanning for pleural abnormalities, potentially leading to better diagnostics for mesothelioma cancer. A research team from the University of Western Australia in Perth has shown the sensitivity of CT scans — used in the diagnostic process — can be improved by creating intrapleural air flow. The discovery stems from their six test cases of malignancies, including four patients with pleural mesothelioma. Chest Journal, the official publication of the American College of Chest Physicians, published the study in June. ...
Source: Asbestos and Mesothelioma News - June 29, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

NIH Opening First Mesothelioma Clinical Trial for Lynparza
The National Institutes of Health (NIH) in Bethesda, Maryland, is opening the first mesothelioma clinical trial involving the immunotherapy drug Lynparza (olaparib), a protein inhibitor and targeted therapy already used effectively with breast and ovarian cancers. The phase II clinical trial, for patients previously treated with standard chemotherapy, is designed to gauge the response rate in pleural and peritoneal mesothelioma. Mesothelioma specialist Dr. Raffit Hassan of the National Cancer Institute (NCI) is the senior investigator for the single-center trial, which hopes to enroll at least 40 patients. Earlier research...
Source: Asbestos and Mesothelioma News - June 27, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Personalized Lung Cancer Screening Tool Adds Asbestos Exposure
A University of Michigan and Veterans Affairs research team has developed a novel, personalized lung cancer screening tool that accounts for past asbestos exposure. Asbestos exposure is best known as the primary cause of mesothelioma, but it also significantly increases the chance of developing lung cancer. Adding asbestos to the lung-cancer screening tool also should help identify mesothelioma in its earliest stages, when it is most treatable. Mesothelioma is not usually diagnosed until it has progressed into stage 3 or stage 4, when treatment is more palliative than potentially curative. The tool is designed to better i...
Source: Asbestos and Mesothelioma News - June 26, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Addressing Suicide Among Cancer Patients
The recent suicides of highly regarded fashion designer Kate Spade and television celebrity chef and author Anthony Bourdain remind us this mental health crisis can touch anyone. Cancer patients are no exception. According to the Centers for Disease Control and Prevention (CDC), suicide rates between 1999 and 2016 have risen more than 30 percent in half of the country and by nearly 60 percent in some states. This trend is particularly worrisome for cancer patients because this group has a higher suicide risk than the general public. For mesothelioma patients and the people who care for them, one part of this picture deser...
Source: Asbestos and Mesothelioma News - June 22, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Tremelimumab and Imfinzi Combo Effective for Mesothelioma
The novel immunotherapy drug mixture of tremelimumab and Imfinzi (durvalumab) produced encouraging results in the first phase II mesothelioma clinical trial examining this combination. The study, which included 40 mesothelioma patients in Italy, was published in the June 2018 edition of The Lancet Respiratory Medicine. Similar — or even more promising — results with this combination are expected to follow soon in the United States. “Results from this study are very promising,” investigator Dr. Luana Calabro, Siena University Hospital, told Asbestos.com. “This regimen also has shown a good safe...
Source: Asbestos and Mesothelioma News - June 20, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Supercharged’ Immunotherapy Could Target Mesothelioma Cell Protein
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - June 18, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Results of Novel Mesothelioma Drug Presented at ASCO Meeting
A multicenter phase II clinical trial involving the latest orally administered protein inhibitor drug has shown considerable promise in helping control malignant mesothelioma. The effectiveness of tazemetostat was presented last week at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago. The trial study, which will conclude late 2018, involves 74 previously treated patients with recurring mesothelioma. “We’ve seen benefit for some patients with this treatment and patients who have benefited over a long period of time,” medical oncologist Dr. Marianna Koczywas, City of Hope Cancer T...
Source: Asbestos and Mesothelioma News - June 14, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Nintedanib ‘ Superior ’ to Bevacizumab for Mesothelioma Treatment
Researchers in Austria, Germany and Hungary have added to the growing belief that the anti-cancer drug nintedanib may soon become a significant part of standard-of-care treatment for malignant pleural mesothelioma. In their study published recently in Clinical Cancer Research, nintedanib demonstrated an ability to inhibit the growth and the migration of mesothelioma tumor cells effectively in animal models. “This is a step in the right direction, another part of the evolutionary process of treatment advancements with this difficult disease,” Dr. Balazs Hegedus, department of thoracic surgery, University of Dui...
Source: Asbestos and Mesothelioma News - June 11, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

‘Right to Try Act’ Could Aid Mesothelioma Patients
Patients with mesothelioma may soon find an easier path to experimental drugs and treatments after President Donald Trump signed the “Right to Try Act” into law last week. The new legislation will give terminally ill patients a more direct and quicker line to drugs still awaiting approval from the U.S. Food and Drug Administration (FDA), bypassing the often-cumbersome application process. The law also will protect doctors and pharmaceutical companies from the legal risks of allowing unapproved treatments. The bill was passed by the Senate in August 2017 and cleared the House of Representatives late last month....
Source: Asbestos and Mesothelioma News - June 6, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

EPA Releases New Rules for TSCA Asbestos Review
As part of the latest updates to the reformed Toxic Substances Control Act (TSCA), the U.S. Environmental Protection Agency (EPA) last week proposed new rules for the risk evaluation of asbestos. The EPA released a significant new use rule (SNUR) proposal which would allow the agency to prevent new uses of asbestos, the naturally occurring mineral linked to deadly cancers such as mesothelioma. It is the first time the EPA has issued such an action. The SNUR would require the agency’s approval before asbestos-containing goods can be manufactured, imported or processed. It would grant the EPA power to evaluate the inte...
Source: Asbestos and Mesothelioma News - June 5, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Could Mesothelioma Chemotherapy Ever Be Obsolete?
Oncologist Dr. Arek Dudek at Regions Hospital Cancer Care Center in St. Paul, Minnesota, believes his clinical trial involving a novel immunotherapy combination could change the way doctors treat pleural mesothelioma. Dudek is opening the only Phase II trial evaluating the combination of nivalumab (Opdivo) and ramucirumab (Cyramza) for previously treated mesothelioma patients. “This strategy – if successful, like we think it will be – could make treatment with chemotherapy obsolete,” Dudek told Asbestos.com. “People can be really excited about this one.” He based his optimism on the pote...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Walter Pacheco Source Type: news

Survey: Most Oncologists Discuss Medical Marijuana with Cancer Patients
Medical marijuana continues to be a hot topic among mesothelioma patients and a popular way to cope with disease symptoms and treatment side effects. As more states legalize marijuana for medicinal purposes, more cancer patients are asking their doctors about the natural therapy. A recent survey published in the Journal of Clinical Oncology shows as many as 80 percent of oncologists talk about medical marijuana with their patients. Of the 237 oncologists who responded to the survey, more than half (55 percent) practice in one of the 28 states where medical marijuana is legal. Questions on the survey covered recommendations...
Source: Asbestos and Mesothelioma News - June 1, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

Facility Expertise Matters for Mesothelioma Surgery
Patients having aggressive surgery for pleural mesothelioma at high-volume facilities experience fewer complications, shorter hospital stays and lower 30-day readmission rates than those treated at low-volume centers. Overall survival rates were higher and 90-day mortality rates were lower at the high-volume facilities, according to a study published in the June issue of Lung Cancer. The new study, based on data from the National Cancer Database (NCDB), is the largest to compare facility volume with post-surgery outcome for pleural mesothelioma. “In general, going to a high-volume center for oncology care makes sens...
Source: Asbestos and Mesothelioma News - May 30, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

South Carolina J & J Baby Powder-Mesothelioma Case Ends in Mistrial
A South Carolina judge declared a mistrial Friday in a high-stakes case blaming asbestos-contaminated Johnson & Johnson Baby Powder for a woman’s mesothelioma. Jurors failed to reach a unanimous decision in the case of Bertila Boyd-Bostic, who was diagnosed with pericardial mesothelioma at the age of 30 and died 15 months later. Bostic’s husband, Antoine Bostic, sued Johnson & Johnson, talc supplier Imerys Talc America and drug store chain Rite Aid, alleging his wife’s death was caused by years of asbestos exposure from inhaling J&J baby powder. The 12-member jury could only reach a unanimous ...
Source: Asbestos and Mesothelioma News - May 29, 2018 Category: Environmental Health Authors: Daniel King Source Type: news

J & J Loses Second Asbestos in Talcum Powder Lawsuit
Johnson & Johnson suffered its second trial loss in two months Wednesday linking the company’s baby powder to deadly asbestos-related cancer. A Los Angeles jury awarded $21.7 million in compensatory damages to Joanne Anderson, who said she developed mesothelioma after being exposed to asbestos in J&J baby powder laced with the carcinogen. J&J was ordered to pay an additional $4 million in punitive damages Thursday, bringing the total award for Anderson to $25.7 million. The verdict comes less than two months after Johnson & Johnson’s first loss in an asbestos-related talcum powder lawsuit. In ...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news

Novel Mesothelioma Treatment Uses Electrical Fields
Oncologists in 2019 may begin offering patients with pleural mesothelioma a novel, tumor-fighting tool involving electric currents that enhance standard-of-care treatment and extend survival, according to the device manufacturer. Tumor Treating Fields (TTF) is the name of the new technology. It is designed to disrupt cancer cell division through electric fields tuned to specific frequencies. In an ongoing multicenter phase II clinical trial in Europe, TTF has shown an ability in first-line treatment to improve the effectiveness of standard chemotherapy for mesothelioma patients. The trial success has led the manufacturer t...
Source: Asbestos and Mesothelioma News - May 24, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news